Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AKTX
stocks logo

AKTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast AKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTX is 4.53 USD with a low forecast of 1.60 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast AKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTX is 4.53 USD with a low forecast of 1.60 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.340
sliders
Low
1.60
Averages
4.53
High
7.00
Current: 0.340
sliders
Low
1.60
Averages
4.53
High
7.00
Maxim
Jason McCarthy
Buy
initiated
$5
2025-07-18
Reason
Maxim
Jason McCarthy
Price Target
$5
2025-07-18
initiated
Buy
Reason
Maxim analyst Jason McCarthy initiated coverage of Akari Therapeutics with a Buy rating and $5 price target.
Maxim
NULL -> Buy
initiated
$5
2025-07-18
Reason
Maxim
Price Target
$5
2025-07-18
initiated
NULL -> Buy
Reason
Maxim initiated coverage of Akari Therapeutics with a Buy rating and $5 price target. The Antibody-Drug Conjugate space is high value at both the commercial and M&A levels, including numerous partnering and licensing deals for preclinical and discovery stage ADC assets, the analyst tells investors in a research note. Combined with challenging biotech markets and broad market headwinds, this story is under-the-radar and just getting started, Maxim argues.
Alliance Global Partners
James Molloy
maintain
$4 -> $7
2025-06-09
Reason
Alliance Global Partners
James Molloy
Price Target
$4 -> $7
2025-06-09
maintain
Reason
Alliance Global Partners analyst James Molloy raised the firm's price target on Akari Therapeutics to $7 from $4 and keeps a Buy rating on the shares. The firm cites its expectations for the company's new antibody drug conjugate centered pipeline following its 2024 merger with Peak Bio for the target increase.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Akari Therapeutics PLC (AKTX.O) is -0.68, compared to its 5-year average forward P/E of 103.89. For a more detailed relative valuation and DCF analysis to assess Akari Therapeutics PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
103.89
Current PE
-0.68
Overvalued PE
364.95
Undervalued PE
-157.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.45
Current PS
0.00
Overvalued PS
2.51
Undervalued PS
-1.62
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AKTX News & Events

Events Timeline

(ET)
2025-12-04
09:20:00
Akari Therapeutics Publishes CEO Update, Advancing New Immuno-Oncology ADC
select
2025-11-18 (ET)
2025-11-18
09:35:49
Akari Therapeutics names Farag as acting CFO
select
2025-11-10 (ET)
2025-11-10
08:47:11
Akari Therapeutics Reveals Mechanism of Action Data for PH1 Presentation
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-04Globenewswire
Akari Therapeutics Advances Novel ADCs, Plans Clinical Trials for AKTX-101 in Q4 2026
  • Innovative Drug Platform: Akari Therapeutics is leveraging its novel antibody-drug conjugate (ADC) platform to develop the PH1 payload, designed to target and disrupt spliceosome function in cancer cells, showcasing a unique preclinical efficacy and safety profile.
  • Clinical Trial Plans: The company plans to initiate IND-enabling studies for AKTX-101 in Q4 2026, which is expected to provide new monotherapy options or combination therapies with checkpoint inhibitors, addressing unmet medical needs in oncology.
  • Survival Extension: Preclinical studies indicate that AKTX-101 significantly prolongs survival both as a single agent and in combination therapies, demonstrating stronger anti-cancer activity compared to traditional ADCs, potentially transforming treatment paradigms.
  • Market Potential: By developing the novel PH1 payload, Akari aims to fill market gaps and meet the demand for innovative cancer therapies, further driving the company's growth in the oncology biotechnology sector.
[object Object]
Preview
5.0
11-18Newsfilter
Akari Therapeutics Names Kameel D. Farag as Interim CFO, Bringing Biotech Finance Expertise

  • New CFO Appointment: Akari Therapeutics has appointed Kameel D. Farag as its Interim Chief Financial Officer, bringing over two decades of experience in biotech and global finance to the role.

  • Company Growth Focus: Farag's expertise in corporate finance and operational build-outs is expected to support Akari's growth as it advances its novel antibody drug conjugate (ADC) platform and lead asset toward clinical development.

  • Innovative ADC Development: Akari is developing a new class of ADCs that utilize spliceosome modulators to disrupt RNA splicing in cancer cells, showing promising preclinical results in inducing cancer cell death and enhancing immune response.

  • Forward-Looking Statements: The announcement includes cautionary notes regarding forward-looking statements, highlighting potential risks and uncertainties that could affect the company's future performance and product development.

[object Object]
Preview
2.0
11-05Benzinga
Teradata Shares Surge Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Teradata Corp Performance: Teradata Corp's shares rose 14.6% in pre-market trading after reporting third-quarter earnings of 72 cents per share, exceeding the analyst estimate of 54 cents, and raising its FY25 EPS guidance above expectations.

  • Other Notable Gainers: Several stocks saw significant pre-market gains, including SMX (up 70%), Nuvve Holding (up 41.3%), and Babcock & Wilcox (up 29.1%), driven by positive financial results and strategic announcements.

  • Major Losers: Biohaven Ltd experienced a sharp decline of 46.2% after receiving an FDA Complete Response Letter, while Trex Company Inc fell 31.9% due to disappointing earnings and lowered sales guidance.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with notable movements in both directions reflecting recent earnings reports and company announcements.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Akari Therapeutics PLC (AKTX) stock price today?

The current price of AKTX is 0.34 USD — it has increased 0 % in the last trading day.

arrow icon

What is Akari Therapeutics PLC (AKTX)'s business?

Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

arrow icon

What is the price predicton of AKTX Stock?

Wall Street analysts forecast AKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTX is 4.53 USD with a low forecast of 1.60 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Akari Therapeutics PLC (AKTX)'s revenue for the last quarter?

Akari Therapeutics PLC revenue for the last quarter amounts to -2.22M USD, increased 20.09 % YoY.

arrow icon

What is Akari Therapeutics PLC (AKTX)'s earnings per share (EPS) for the last quarter?

Akari Therapeutics PLC. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Akari Therapeutics PLC (AKTX)'s fundamentals?

The market is revising No Change the revenue expectations for Akari Therapeutics, Plc (AKTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -58.47%.
arrow icon

How many employees does Akari Therapeutics PLC (AKTX). have?

Akari Therapeutics PLC (AKTX) has 8 emplpoyees as of December 05 2025.

arrow icon

What is Akari Therapeutics PLC (AKTX) market cap?

Today AKTX has the market capitalization of 12.15M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free